Rodman & Renshaw Assumes OncoSec Medical Inc to Buy

Brokerage firm Rodman & Renshaw Assumes its rating on OncoSec Medical Inc(NASDAQ:ONCS). The shares have been rated Buy. The rating by Rodman & Renshaw was issued on Jul 21, 2016.

OncoSec Medical Inc (ONCS) made into the market gainers list on Wednesdays trading session with the shares advancing 0.61% or 0.01 points. Due to strong positive momentum, the stock ended at $1.64, which is also near the day’s high of $1.67. The stock began the session at $1.64 and the volume stood at 28,936 shares. The 52-week high of the shares is $6.94 and the 52 week low is $1.36. The company has a current market capitalization of $29 M and it has 1,76,36,263 shares in outstanding.

OncoSec Medical Inc(ONCS) last announced its earnings results on Jun 9, 2016 for Fiscal Year 2016 and Q3.Earnings per share were $-0.37. Analysts had estimated an EPS of $-0.43.

Several Insider Transactions has been reported to the SEC. On Oct 19, 2015, Avtar S Dhillon (director) purchased 10,000 shares at $4.36 per share price.Also, On Oct 19, 2015, Sheela Mohan-peterson (Chief Legal Officer) purchased 520 shares at $4.24 per share price.On Oct 19, 2015, Punit Dhillon (CEO) purchased 10,000 shares at $4.23 per share price, according to the Form-4 filing with the securities and exchange commission.

OncoSec Medical Incorporated is a biotechnology company focused on designing developing and commercializing gene therapies therapeutics and medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer. The Company’s portfolio includes biologic immunology therapeutic product candidates intended to treat a range of tumor types. The Company’s technology includes property relating to its ImmunoPulse delivery technology. The Company’s ImmunoPulse is an electroporation delivery device that the Company uses in combination with its therapeutic product candidates including deoxyribonucleic acid (DNA) plasmids that encode for immunologically active agents to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer. Its electroporation devices consist of an electrical pulse generator and disposable applicators. The Company’s ImmunoPulse product candidates are based on its DNA based immunotherapy technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *